We report here the complete genome sequence of raccoonpox virus (RCNV), a naturally occurring North American poxvirus. This is the first such North American sequence to the best of our knowledge, and the data showed that RCNV forms a new phylogenetic branch between orthopoxviruses and Yoka poxvirus. RCNV shared overall similarity in genome organization with orthopoxviruses, and the proteins in the central conserved region shared approximately 90 % amino acid identity with orthopoxviruses. RCNV proteins shared approximately 81 % amino acid identity with Yokapox virus proteins. RCNV is missing 10 genes normally conserved in orthopoxviruses, most of which are implicated in virulence. These gene deletions may explain the attenuated phenotype of RCNV in mammals. RCNV contained one unique genome region containing approximately 1 kb of DNA sequence that is not present in any reported poxvirus. It contained a unique ORF predicted to encode a protein with a transmembrane domain. RCNV replicates well in mammalian cells, is naturally attenuated and has been shown to be effective as a vaccine vector platform, so we further tested its safety. We showed here that RCNV is substantially more attenuated than even the highly attenuated VACV-A35Del mutant virus in pregnant, nude and severe combined immunodeficient (SCID) mouse models. RCNV was much safer in pregnant mice and was cleared rapidly from tissues, even in immunocompromised animals, whereas the VACV-A35Del mutant retains virulence and persists in tissues. Thus, RCNV is expected to be a superior vaccine vector for infectious diseases and cancer due to its excellent safety profile, reported vaccine efficacy and ability to replicate in mammalian cells.
INTRODUCTION
Poxviruses cause disease in humans and animals worldwide. Smallpox is estimated to have killed 500 million people during the 20th century, but it was eradicated from nature by 1980 by a robust vaccination programme headed by the World Health Organization (Mahalingam et al., 2004) . Most extant human-infecting poxviruses are zoonotic, transmitted mostly via rodents, including monkeypox, which caused an outbreak in the US midwest in 2003 with more than 80 cases (Chen et al., 2005; McCollum & Damon, 2013) . Monkeypox virus is endemic in Africa and has a case fatality rate that varies according to the age of the patient but can reach approximately 10% (Chen et al., 2005; Lederman et al., 2007) . Cowpox (CPXV) and Orf viruses also infect humans, but these infections are rarely fatal (Lewis-Jones, 2004) . Molluscum contagiosum virus is only known to infect humans, is common worldwide and is emerging as a sexually transmitted disease (Molino et al., 2004; Senkevich et al., 1997) . New poxviruses are identified each year in animal populations, and several zoonotic poxviruses appear to be emerging worldwide in humans (Shchelkunov, 2013) , such as Cantagalo virus in South America (Damaso et al., 2000; Oliveira et al., 2013) , Tanapox virus in Africa (and also detected in Europe and the USA among travellers) (Dhar et al., 2004; Stich et al., 2002) and buffalopox virus in India (Kolhapure et al., 1997) .
Poxviruses are often used as recombinant vaccine vectors for infectious diseases and cancer therapies (Campbell et al., 2013 Carol, 2013). The only human immunodeficiency virus vaccine with efficacy so far uses a canarypox vector (RerksNgarm et al., 2009) . Poxviruses such as vaccinia virus (VACV) are suitable as vectors because they are easily grown to high titre in a wide variety of animals and cell types, can accommodate insertions of large pieces of DNA into their genomes, are very stable even when dried and induce a robust T-cell immunity (Tscharke et al., 2005) . VACV is the most commonly used poxvirus vaccine vector; however, its use is limited by its potential virulence, especially in immunocompromised hosts. The Modified Vaccinia Ankara (VACV-MVA) strain is much more attenuated, but its replicative capacity and immunogenicity are limited (Belyakov et al., 2003; Earl, et al., 2004; Guzman et al., 2012; Hatch et al., 2013; Hersperger et al., 2014; Jones-Trower et al., 2005; Tscharke et al., 2005; Weltzin et al., 2003) .
Raccoonpox virus (RCNV) is a naturally occurring attenuated North American poxvirus; thus, it is of interest evolutionarily, as a vaccine vector platform and for its oncolytic therapy potential (Evgin et al., 2010) . The RCNV strain Herman was originally isolated from apparently healthy raccoons (Hermans, 1964) and has been shown to be avirulent in numerous animal models. The reason(s) for this attenuation is unknown, and no native North American poxvirus has been sequenced previously. Recombinant RCNV vaccines have been successfully employed in mice, raccoons, skunks, foxes, bobcats, rabbits, domestic cats, piglets, sheep and non-human primates (DeMartini et al., 1993; Esposito, 1989; Fekadu et al., 1991; Hu et al., 1997; Lodmell et al., 1991; Osorio et al., 2003b) . In addition, recombinant RCNV has been shown to induce protective immune responses in domestic cats against feline panleukopenia virus, feline caliciviruses and feline infectious peritonitis virus (Hu et al., 1997; Wasmoen et al., 1995) . RCNV-vectored rabies vaccine has also been administered via oral, intranasal and conjunctival routes as a mucosal vaccine in cats and was found to be safe (Osorio et al., 2003a) . A rabies-RCNV vaccine has been approved by the US Department of Agriculture.
We have recently reported that RCNV is less virulent and much safer than VACV in immunocompromised or pregnant mouse models (Jones et al., 2014) . This is important because VACV infection can be fatal, especially in immunocompromised or pregnant humans, and it is contraindicated for such individuals. Here we provide the genome sequence of RCNV to provide insight into its attenuation and facilitate diagnostics, recombinant DNA strategies, and drug and vaccine design. In addition, we compared the virulence of RCNV and the highly attenuated VACV-A35Del mutant, which is missing the immunoregulatory A35R gene (Rehm et al., 2010a, b; Roper, 2006) . We employed two commonly used immunocompromised mouse models. Nude mice are deficient in functional mature T-lymphocytes and therefore do not mount an effective antiviral cytotoxic T-cell or helper T-lymphocyte response. Severe combined immunodeficient (SCID) mice are missing both T-lymphocyte-and B-lymphocyte (antibody)-specific immune responses. The RCNV and VACV-A35Del mutants both replicated in mammalian cells, were attenuated compared with VACV, and are candidate oncolytic and vaccine vector platforms. Our data indicated that whilst the VACV-A35Del might not be safe to use in immunocompromised or pregnant mammals, RCNV presents a safer option because RCNV is much more highly attenuated in nude, SCID and pregnant mice.
RESULTS

Genome sequencing and phylogenetic tree
The RCNV genome was assembled into a single contig of 214 699 bp. It possessed inverted terminal repeats (ITRs) of 18 953 bp, larger than any currently described for orthopoxviruses. However, the coding capacity (unique+one copy of the ITR) was close to the middle of the orthopoxvirus range. At 67.7 % for the mean A+T content, this RCNV genome is at the higher end of the range for previously sequenced orthopoxviruses, but, as with other orthopoxviruses, there was considerable variation among the individual RCNV genes (57-75 mol% A+T). The overall genome organization of RCNV was very similar to that of the orthopoxviruses, and most genes were found in identical syntenic positions when compared with the CPXV or VACV genomes. This relationship was demonstrated by a similarity dot plot (Fig. 1) , generated by JDotter (Brodie et al., 2004a) , in which insertions and deletions 1 24000 1 24000 48000 72000 96000 120000 144000 168000 192000 48000 72000 96000 120000 144000 168000 192000 (indels) can be seen as breaks in the diagonal 'identity line' between the two genomes. The large gap in the upper left area of the line indicated a deletion in RCNV relative to CPXV, and the large gap in the lower right indicated a deletion in CPXV relative to RCNV (discussed in detail below). The shorter lines in the upper right and lower left indicated the similarities in the ITRs.
Using either the central DNA sequences (approx. 100 kb) or a set of 12 conserved concatenated protein sequences (detailed in Methods), RCNV was placed between the orthopoxviruses and Yokapox virus (YKV) (Fig. 2) in a phylogenetic tree. YKV was isolated from mosquitoes in Africa in 1972 and can replicate in mammalian cells and kill suckling mice (Zhao et al., 2011) . This position in the tree is similar to that identified previously using single gene sequences (Emerson et al., 2009; Gallardo-Romero et al., 2011) . Using the same set of concatenated protein sequences, this translated to approximately 93% amino acid identity between RCNV and the orthopoxviruses, which share approximately 98% amino acid identity among themselves (Table 1) . Similar comparisons yield 81% amino acid identity between RCNV and YKV, and 70% amino acid identity between RCNV and myxoma (MYXV), goat (GTPV) or swine (SWPV) poxviruses. However, this overview of similarity between viruses hid a multitude of subtle but important differences that became apparent after complete annotation of the genome.
Genome annotation
A total of 208 ORFs were annotated in the RCNV genome. Twelve ORFs are duplicated in each of the ITRs (Table 2) ; of these, three were gene fragments. Comparing the number of genes in the different poxvirus genomes can be misleading because of the different standards applied to the annotation process by different research groups. As this is the first North American poxvirus sequenced to the best of our knowledge, care was taken not to miss potential new genes; annotating these potential genes makes them more accessible for analysis and confirmation or rejection by virology/biochemistry. However, we avoided annotating small ORFs that overlapped known genes and that lacked any evidence of expression. Thus, our initial analyses were to: (i) look for novel RCNV ORFs that could represent novel genes in this virus; and (ii) review the virulence genes missing from RCNV that might explain its relatively attenuated phenotype. However, it is important to remember that changes to gene expression due to single-nucleotide polymorphisms in promoters or minor changes to protein sequences might affect functions or interactions with host proteins and could be Fig. 2 . Unrooted phylogenetic tree of concatenated protein sequences from core genes within poxvirus genomes. The neighbour-joining method of MEGA5 with 1000 bootstrap replicates was used to reconstruct the tree. ECTV, ectromelia virus; GTPV, goatpox virus; MYXV, myxoma virus; RPXV, rabbitpox virus; SWPV, swinepox virus; VARV, variola virus. Strain designations are given after the virus abbreviation.
responsible for attenuation in certain hosts. This cannot yet be fully evaluated en masse using bioinformatics tools.
The global similarity of RCNV to each of the orthopoxviruses, when assessed from aligned sequences, was approximately the same; however, the RCNV genome appeared to be more similar overall to CPXV genomes than to VACV genomes with regard to genome size and ORF/gene conservation. This was most noticeable at the genome termini in the comparison of RCNV genes present in CPXV-BR and VACV-Cop (Table 2 ). Genes present in RCNV and CPXV-BR but absent from VACVCop encoded a lectin domain protein (RCNV-009), a TNF a-receptor-like protein (RCNV-010), several ankyrin repeat-containing proteins (RCNV-011, -012 and -014) and a large predicted surface glycoprotein, RCNV-196 (Table 2 ). There was also one more centrally located gene that was missing in VACV-Cop but present in RCNV and CPXV, the A-type inclusion protein (RCNV-141). To fully appreciate the differences, it was also necessary to take into account the fragmentation of genes in the various genomes (Table 2) .
Unique sequences
Although the majority of the RCNV genome matched sequences present within orthopoxviruses, the RCNV genome contained a unique 1 kb region encoding a single novel ORF (ORF171) that is not present in any other poxvirus sequenced to date. This insertion was barely visible on a dot plot comparing equivalent regions of CPXV, YKV, camelpox virus (CMLV) and variola virus (VARV) (Fig.  S1 , available in the online Supplementary Material) because the sequence is relatively small and replaced the similarly sized CPXV TNF receptor/CrmC gene. This novel ORF is oriented such that it would be transcribed from left to right in the standard poxvirus model and is predicted to encode a 185 aa protein (21.7 kDa, pI 6.4). This protein was predicted to have at least one C-terminal transmembrane domain by several programs [HMMTOP (Tusnády & Simon, 2001) , TMHMM (Krogh et al., 2001) and SOSUI (Hirokawa et al., 1998) ] but no classical signal peptide. The number of transmembrane domains and the orientation of the protein in the membrane were disputed by the prediction programs (Fig. 3) .
A comparison of DNA sequences surrounding this gene in YKV and orthopoxviruses revealed considerable heterogeneity (Fig. S1 ). The RCNV gene was flanked by the genes encoding the Toll/IL1 receptor-like protein (VACV-Cop A52) on the left (59 side) and the BTB kelch domain protein (VACV-Cop A55) on the right (39 side). The arrangement of these flanking genes was the same in VACV and CPXV, but the RNCV ORF171 was within a 1 kb DNA region that is unique to RNCV; in the orthopoxviruses, these flanking genes surround a similarly sized stretch of DNA that encodes crmC (TNF receptor-like protein). Although the numbering of ORFs in VACV-Cop suggests this region is larger, two of the numbered ORFs were small and are unlikely to be functional genes. BLASTP, PSI-BLAST and BLASTX (Altschul et al., 1997; Ye et al., 2006) searches of the protein databases with the RNCV ORF171 predicted protein found no significant matches. InterPro searches for protein motifs only reaffirmed the prediction of a C-terminal transmembrane domain with no signal sequence (Hunter et al., 2012) . BLASTN searches of the DNA database similarly failed to detect any significantly similar sequences, yielding no clues as to the function or provenance of this ORF. Interestingly, the two flanking genes are also conserved in the YKV genome, but these surround yet another unique region of slightly more than 1 kb DNA. This encodes an ornithine decarboxylase-like protein that is unique to YKV. The variability of this region was illustrated by a series of dot plots that provided pairwise comparisons of the DNA sequences (Fig. S1 ). Interestingly, the CMLV and VARV genomes had deletions in this region, as reflected in the size of the area of comparison.
The only other gene that was found in RCNV but is absent from the orthopoxviruses was RCNV 008/201 (left and right ITRs, respectively); however, an orthologue is present in YKV (58% amino acid identity; endoplasmic reticulum localized and inhibits NF-kB activation). These genes appeared to be distant paralogues (approx. 30% amino acid identity) of the family of proteins that is encoded by orthologues of the RCNV 027 gene (VACV-Cop M2L). There are no known host counterparts of these genes, so it is difficult to establish a lineage; however, it is possible that the RCNV 008L/201R genes evolved from duplication of an ancient poxvirus gene in a direct ancestor of RCNV and YKV.
Virulence genes
Evolutionarily, it is interesting to see which virulence genes are conserved and why RCNV might be so attenuated in a variety of mammals, especially because this lack of virulence makes it attractive as a vaccine. This is a difficult undertaking, considering the complexity of the poxviruses and the number of genes and pathways involved in virus virulence (Smith et al., 2013) , and as RCNV is relatively distantly related to all other poxviruses, there is no closely related virus to use as standard measure of 'virulence'. Also, the question itself is somewhat troublesome because RCNV obviously successfully infects its natural hosts in the wild and is able to continue a chain of transmission. Therefore, perhaps a better way to examine this subject is to consider why the virus produces only a mild infection in such a wide variety of hosts whereas a number of viruses appear to be more virulent when they 'jump hosts' (e.g. human immunodeficiency virus, Ebola virus, MYXV and influenza viruses ; Feldmann & Feldmann, 2013; Haller et al., 2014; Holmes & Drummond, 2007) . There are 10 genes present in most orthopoxviruses but absent from RCNV; the majority of these proteins are known to function in aspects of virus virulence: putative TLR signalling (CPXV10), hypothetical (CPXV18), ankyrin (Cop-B18R, CPXV19), VARV-Bang D3L (CPXV20), secreted EGFlike (CPXV21), zinc finger-like (CPXV23), soluble IL-18 binding (CPXV24), ankyrin/host range (CPXV25), C-type lectin type II membrane (CPXV183) and TNF receptorlike CrmC (CPXV197). The CrmC gene in CPXV is replaced by the unique ORF in RCNV.
These missing genes include CPXV ORF18-25 deleted in the left end of RCNV, as shown in Fig. 1 . However, as the non-essential RCNV proteins only share about 70% amino acid identity with their orthopoxvirus counterparts, in contrast to the most conserved proteins, which are about 90% conserved, it is clear that this level of variation could also have a significant influence on host-range virulence differences.
The poxviral ITRs are notoriously variable, both in length and in gene content; genes may be absent by virtue of deletion of DNA segments or fragmented due to mutations or indels that cause premature termination codons. Table 2 shows the absence of genes due to an approximately 8 kb deletion from the RCNV left ITR compared with CPXV-BR (CPXV ORF18-25) and in the dot plot (Fig. 1, upper  left) . In RCNV, these genes are 'replaced' by insertion of a partial duplicate copy (RCNV-013f) of the 1902 aa predicted surface glycoprotein gene (RCNV ORF196, orthologue of VARV B22R) that spans the right-hand ITR junction with the unique central section of the genome, whereas the left-hand ITR junction removes the natural promoter and the DNA encoding more than 600 of the N-terminal amino acids. The position of the ITR junction causes the fusion of an 82 codon ORF to the remainder of this large gene, which results in loss of the protein signal sequence from the predicted protein sequence (SignalP v.4.1; Petersen et al., 2011) . This ORF has an AT-rich region in place of the natural promoter, but whether transcription takes place is unknown. The insertion in the RCNV genome relative to CPXV (Fig. 1) does not introduce any new genes as these genes are found at the left end of CPXV.
Virulence in T-lymphocyte deficient nude mice
Generally, the RCNV genome appeared similar in sequence, A+T composition and arrangement/size of ORFs to CPXV-BR, which is a virus that has significant virulence in mice and other mammals and is thought to contain close to a full complement of orthopoxvirus virulence genes. Although the RCNV genome is larger than the VACV-WR genome, the latter causes much higher morbidity and mortality in mice. As RCNV is a safe and effective vaccine in normal mice (Lodmell et al., 1991; Osorio et al., 2003b) , we further tested RCNV in immunodeficient mice and compared it with virulent VACV-WR and with an A35 deletion mutant virus (A35Del), which is attenuated 100-1000-fold compared with VACV-WR although it replicates equally well (Rehm et al., 2010a; Roper, 2006) . RCNV contains a full-length A35 orthologue (RCNV ORF151). In vaccinia, the A35R gene has been shown to block MHC class II antigen presentation in vitro and antibody and T-lymphocyte responses in vivo (Rehm & Roper, 2011; Rehm et al., 2010a, b) suggesting that the use of A35Del virus as a vaccine platform or oncolytic virus would improve both safety and efficacy. Here, we directly compared these two potential oncolytic and vaccine candidates. Athymic nude mice are immunodeficient because they lack T-lymphocytes. Mice were infected intranasally (i.n.) with one of the following: virulent WT VACV-WR, VACV-A35Del (1|10 3 p.f.u. per mouse), 70 times as much WT RCNVHerman or RCNV-Herman with the thymidine kinase (TK) gene deleted (RCNV-Herman-TK 2 , 7|10 4 p.f.u. per mouse) or a PBS control. Morbidity (weight loss) and mortality were monitored for 94 days. As shown in Fig. 4(a) , the PBS mice continued to gain weight throughout the experiment. Mice infected with VACV-WR began losing weight on day 7, and by day 14, five out of six mice had lost 20% of their body weight and were sacrificed (the remaining mouse reached the end point and had to be euthanized at day 25; Fig. 4b ). The VACV-A35Del-infected mice showed a 1-week delay in weight loss, losing weight around day 14, and five out of six mice required sacrificing by day 18 (the remaining mouse reached the end point at day 25; Fig. 4b) . However, the WT RCNVHerman-infected mice gained weight up to day 30 when some mice began losing weight. Five out of six RCNV-Herman-infected mice required sacrificing between days 33 and 87 (one remained alive up to day 94 when the experiment was terminated). This set of data indicated that WT RCNV (strain Herman, which is not attenuated by genetic engineering) is naturally highly attenuated compared with VACV-WR and is even safer than the highly attenuated VACV-A35Del virus, even when used at a dose 70 times higher. However, the WT RCNV-Herman eventually killed T-cell-deficient mice, perhaps by outgrowth of more virulent viral mutants that were selected during extended virus replication in the mouse. All immunodeficient mice infected with RCNV-Herman-TK 2 mutants were healthy to the end of trial (day 94) with no signs of infection. Whilst the VACV-A35Del might not be safe to use in immunocompromised humans, RCNV appears to be a safer option.
SCID mice
Virulence was assessed next in severely immunocompromised SCID mice, which are deficient in both B-and Tlymphocytes. SCID mice were infected i.n. with one of VACV-WR, VACV-A35Del, RCNV-Herman, RCNVHerman-TK 2 (all at 1|10 3 p.f.u. per mouse), or with PBS as a control. Weight loss and mortality were monitored for 174 days. The RCNV-infected mice were healthy and gained weight, whilst the VACV-WR-infected mice began losing weight around day 7 (Fig. 5a ). Six out of seven mice infected with VACV-WR required sacrificing by day 13, and one died later (Fig. 5b) . The VACVA35Del-infected mice showed a delay of only about 1 week. Incredibly, RCNV (Herman and TK 2 ) showed no morbidity or mortality up to day 174. Thus, RCNV is extremely attenuated, even compared with the mutant VACV-A35Del, and 1|10 3 p.f.u. did not kill even severely immunocompromised mice after almost 6 months. At this dose, even the WT RCNV-Herman was avirulent.
A second experiment was performed in SCID mice to determine whether these viruses could replicate and persist in the organs of SCID mice. We chose day 10 for measuring organ titres, as the VACV-WR-infected mice were sick but still alive at this time point in the first experiment. VACV-WR-infected mice had very high titres of virus (w10 4 p.f.u. per organ) in the brain, heart, lung and nose (Fig. 6a) . The attenuated VACV-A35Del virus also showed significant organ titres, w10 4 p.f.u./lung, w10 3 in brain and heart. In contrast, almost all of the RCNV-infected groups of mice cleared the virus completely by day 10 p.i. In the RCNV-Herman-TK 2 -infected group, only two of the mice still had detectable virus in the heart (mean of v100 p.f.u./heart) at day 10. This was a significant reduction compared with VACV-WR (Pv0.05). These data indicate that whilst RCNV can replicate in mice, RCNV do not persist in most mouse tissues, even in severely immunocompromised SCID mice. There is apparent transient infection, and viruses can be cleared, possibly by the innate immunity.
Pregnant mice
VACV vaccination is contraindicated in pregnant women because VACV can infect and kill fetuses. Therefore, as RCNV was so much less virulent than the attenuated VACV-A35Del in immunocompromised mice, we tested the safety of these viruses in a pregnant mouse model (Benning & Hassett, 2004) . Pregnant BALB/c mice were injected i.p. with VACV-WR, VACV-A35Del, RCNV-Herman or RCNV-Herman-TK 2 , or PBS on the 12th day of pregnancy. Births occurred near day 20, but some pups died shortly after birth. Live pups were counted on day 26 post conception (Fig. 6b) . Control mice delivered on average 5 or 6 viable pups, and infection with either VACV-WR or the attenuated VACV-A35Del reduced live pup survival significantly (Pv0.01) compared with PBS-injected mice to about one per litter. RCNV-Herman-and RCNVHerman-TK 2 -infected mice produced three to four viable pups on average per litter, but this was not significantly different from the PBS results. Pups that survived past day 26 appeared normal and healthy until day 31, when they were sacrificed. These data showed that deletion of the A35 gene in VACV-A35Del did not attenuate infection mortality in this model and that RCNV was much safer than even the highly attenuated VACV in a pregnant mouse model.
DISCUSSION
Here, we have described the RCNV genome sequence, the first North American poxvirus to be sequenced to the best of our knowledge. The analysis showed that this virus was most closely related to orthopoxviruses; however, RCNV was considerably more distantly related to this group than the other viruses already placed within the orthopoxviruses, forming a branch between YKV and the orthopoxviruses. The overall arrangement of genes within the genome was similar to that of CPXV, and RCNV possessed orthologues of most CPXV genes. There was only one region within the RCNV genome that contained completely novel DNA (to date), a region of approximately 1 kb. Interestingly, this region replaced the sequence encoding a TNF receptor-like protein (Crm C) in CPXV and another unique region of DNA in YKV that encodes an ornithine decarboxylase-like protein. The RCNV segment contained an ORF that was predicted to encode a protein of 185 aa, with predicted C-terminal transmembrane domain(s). This ORF and its potential unique protein await characterization. Another large-scale genome event was represented by the organization of the ITRs, with duplication of the large gene encoding a predicted surface glycoprotein and modification of the left-end copy of this gene by the ITR junction. Compared with CPXV, an 8 kb deletion within the RCNV ITR removed genes that encode the zinc finger-like, secreted EGF-like and soluble IL-18-binding proteins together with two ankyrin-like proteins.
RCNV was more similar to CPXV than to VACV, which have smaller genomes, by virtue of genome structure rather than sequence similarity; RCNV was attenuated compared with these viruses, although it still replicated well in mammalian cells (Jones et al., 2014) . RCNV has been shown to be less virulent in immunocompetent and immunodeficient mouse models, and we showed here that RCNV was highly attenuated, even compared with VACV-A35Del, which is 100-1000-fold less virulent than the parental VACV-WR (Roper, 2006; Rehm et al., 2010a) . Whilst VACV-A35Del persists in SCID mouse tissues 10 days after infection, RCNV was almost completely cleared. Also important for consideration of vaccine safety, RCNV was much less lethal for mouse pups in utero, whereas the highly attenuated VACVA35Del caused high loss of pup viability. The RCNV-challenged pregnant mice delivered almost the same number of viable pups as PBS-treated mice, thus suggesting that RCNV will make a superior poxvirus vaccine vector with improved safety and good efficacy (DeMartini et al., 1993; Esposito, 1989; Fekadu et al., 1991; Hu et al., 1997; Lodmell et al., 1991; Osorio et al., 2003a, b) . These data suggest that RCNV would be much safer in humans, but further experiments are needed. Interestingly, whilst the WT Herman strain was highly attenuated, deletion of the TK gene attenuated it further (as is the case in VACV; Lee et al., 1992) .
We found 10 genes conserved in most orthopoxviruses that were missing in RCNV that could individually or in combination explain the profound lack of virulence of RCNV. VACV, CPXV and ectromelia virus (ECTV), which all cause significant morbidity and mortality in mice, contain three genes (zinc finger-like, secreted EGFlike and soluble IL-18-binding proteins) that were absent from RCNV. However, it is possible that there are many other differences, including single-nucleotide polymorphisms (affecting protein function, protein-protein interactions and gene promoter strength) that could also be affecting viral pathogenesis. As a result of the mild nature of RCNV infections in the wild, the virus has largely gone unnoticed, and little is known about its natural host range. Clearly RCNV is evolutionarily successful and must be produced at sufficient levels to maintain a transmission chain, but it is not known why the virus exhibits low pathogenesis. This could be due to low levels of replication or failure to infect critical organs. Molluscum contagiosum virus, a human poxvirus from a different genus, also transmits efficiently and produces minimal pathogenesis; it is limited to the skin, avoids the immune system and persists for long periods of time (Senkevich et al., 1997) . Many of the poxviruses with a limited host range tend to have smaller genomes and therefore it is possible that RCNV is adapted to a variety of hosts; this could be consistent with the lack of severe pathogenesis in a variety of animals.
Analysis of the mammalian immune response to RCNV will be interesting and important, especially in light of the fact that RCNV is missing several proven or putative immunoregulatory poxvirus genes, including the soluble IL-18-binding, TLR signalling and TNF receptorlike proteins. These are likely to have broad effects on both innate and adaptive immune responses. In addition, it will be important to determine whether the anti-VACV and anti-RCNV T-lymphocytes and antibodies are cross-reactive. It is unknown whether vaccination with RCNV will protect against VACV or other orthopoxvirus infections.
All studies comparing the gene content of viruses with the hope of dissecting contributing factors of host range and virulence depend heavily on the correct annotation of the viruses. Several factors other than the presence/absence of genes that can affect gene function have been mentioned above, but it should also be noted that gene extensions are common in poxviruses, and some genes appear to have been built by fusion of domains (Nicholls & Gray, 2004) . Therefore, simply because a gene is shorter relative to another orthologue does not necessarily mean that it is non-functional in its fragmented form.
METHODS
Viruses. The Western Reserve strain of VACV (VACV-WR) was obtained from the NIH Laboratory of Viral Disease. VACV-A35Del was derived from VACV-WR by deletion of the A35R gene (Roper, 2006) . RCNV strains Herman and Herman-TK 2 were obtained from Boehringer Ingelheim Vetmedica. VACV-WR was grown in BS-C-1 cells and RCNV strains were grown in Vero cells. VACV and RCNV preparations were purified on sucrose gradients, aliquotted and titrated three times on BS-C-1 cells (Roper, 2006) .
Virus DNA preparation and DNA sequencing. RCNV-Herman DNA was extracted from two virus preparations and Illumina-based technology was used to generate *200 000 000 sequencing reads, of which *2.0% were RCNV. The sequencing data from the two samples (247| and 487| coverage) were pooled to generate a reference genome. Verification of DNA sequence and surrounding problem areas was performed either based on raw Illumina data or by PCR and traditional Sanger sequencing (positions 32 500-34 100 and 176 000-177 500). Regions of low complexity such as tandem repeats, ITRs or duplications were identified using coverage depth analysis with a 100 bp sliding scale window (NextGene software version 2.3.4; Softgenetics). In total, 14 regions with indicative spikes in coverage depth were resolved using a combination of mate-pair sequence analysis and/ or PCR amplification from flanking sequences followed by Sangerbased sequencing.
Genome annotation was completed using the following software: Viral Orthologous Clusters (VOCs) (Ehlers et al., 2002; Upton et al., 2003) , Genome Annotation Transfer Utility (GATU) (Tcherepanov et al., 2006) , Viral Genome Organizer (VGO) (Upton et al., 2000) , and Base By Base (BBB) (Brodie et al., 2004b; Hillary et al., 2011) available from the Virology.ca Bioinformatics Resource (http://athena.bioc. uvic.ca/). Several of the larger orthopoxviruses (especially CPXV) were used as reference genomes for the annotation process; care was taken to evaluate possible consequences of truncations or extensions at the N and C termini of predicted proteins and to compare ORFs with the families of orthologues rather than with a single reference strain. Most ORFs were easily matched to orthologues in other poxviruses using BLAST results (Altschul et al., 1990) ; unassigned DNA sequences were examined for novel ORFs. Multiple sequence alignments were generated using MAFFT (Katoh & Standley, 2013; Katoh et al., 2009) .
Phylogeny. A neighbour-joining phylogenetic tree (Saitou & Nei, 1987) was derived from a multiple protein sequence alignment created with a set of 13 concatenated protein sequences [DNA polymerase, DNA topoisomerase type I, RAP94, DNA helicase, transcript release factor, RNA polymerase (RPO132), RNA helicase, DExH-NPH-II domain, essential Ser/Thr kinase (Cop-F10L), Holliday junction resolvase, FEN1-like nuclease, RNA polymerase (RPO147) and uracil-DNA glycosylase]. Gap columns were removed from the protein alignment and 1000 bootstrap replicates (Poisson model) were completed using MEGA5 (Tamura et al., 2011) . Genomes comprised: ECTV-Moscow (GenBank accession no. NC_004105), CPXV-Ger98-2 (HQ420897), CPXV Brighton Red (CPXV-BR; NC_ 003663), MYXV-BRK (JX565562), SWPV-Neb (NC_003389), GTPVPellor (NC_004003), YKV-DakArB (HQ849551), VARV-Harv (DQ 441444), CPXV-FIN (HQ420893), VACV-Cop (M35027), RPXV-Utr (AY484669) and VACV-WR (NC_006998).
Nude mice. All experiments involving animals were approved by the East Carolina University Animal Care and Use Committee (K157) and performed in AALAC-accredited facilities. Groups (n56) of 3-5-week-old nude mice (Charles River Laboratories) were anaesthetized using isoflurane and infected i.n. on day 0 with purified virus in 18 ml or were mock infected with PBS. VACV-WR and VACVA35Del were used at 1|10 3 p.f.u. per mouse (Roper, 2006) , and RCNV strains were used at 7|10 4 p.f.u. per mouse. Titres were confirmed for each experiment by titrating the dilution used to infect the mice that day. Mice were weighed and monitored daily for 94 days and euthanized if 20% weight loss occurred. SCID mice. Groups (n56) of 3-5-week-old SCID mice (Jackson Laboratories) were anaesthetized and infected i.n. on day 0 with purified virus or were mock infected with PBS. VACV-WR and RCNV strains were used at 1|10 3 p.f.u. per mouse. Titres were confirmed on the day of the experiment. Mice were weighed and monitored daily for 174 days and euthanized if 20% weight loss occurred.
SCID mice organ titre infection. To determine virus titres in organs, groups (n54) of 3-5-week-old SCID mice were infected i.n. with VACV-WR and VACV-A35Del at 1|10 3 p.f.u. per mouse,or with RCNV-Herman or RCNV-Herman-TK 2 at 4|10 3 p.f.u. per mouse in 18 ml. Mice were weighed daily for 10 days and sacrificed. Organs were placed in 1 ml ice-cold RPMI medium, frozen and thawed three times, homogenized (Omni Tissue Master 125) and sonicated as described previously (Rehm et al., 2010a) . Virus replication was evaluated by titration of the organ on BS-C-1 monolayers and staining with 0.1% crystal violet in 20% ethanol after 40-48 h. VACV and RCNV formed similar-sized plaques.
Pregnant mice. Groups of pregnant BALB/c mice (n55-8 per group) were injected intraperitoneally with 8|10 6 p.f.u. VACV-WR, VACV-A35Del, RCNV (Herman or TK 2 ) or PBS on day 12 of pregnancy, similar to published models (Benning & Hassett, 2004) . Mice were monitored daily and live pups were counted. Births occurred over several days around day 20. Data are the numbers of live pups on day 26 after conception. Pups counted on that day were of normal size and survived up to day 31 when sacrificed (approx. day 11 post-delivery). Statistical differences were measured by a two-tailed Student's t-test.
